https://www.selleckchem.com/products/azd3229.html
Vor Biopharma secured $110 million in July to move its CD33-inactivated cell therapy into clinical testing. The company's hope is that patients with high-risk acute myeloid leukemia who receive transplants of the gene-edited stem cells will then better tolerate therapies designed to destroy cells expressing CD33, an antigen found in abundance on leukemic blasts.The U.S. Preventive Services Task Force recently proposed guidelines that would expand the criteria for lung cancer screening by reducing the requirements for age and smoking his
כמו
תגובה
לַחֲלוֹק
